← Back to Home

Helping the Immune System Accept a Transplanted Liver: UCLA Trial Explores Stopping Anti-Rejection Drugs

A strategy adapted from kidney transplantation involves infusing blood-forming stem cells from the original donor into the recipient to try to establish immune tolerance. This liver transplant trial, which plans to enroll 12 people, must first answer whether patients can safely stop medication while preserving the transplanted organ.

By SURL BioNews

For organ transplant patients, life after successful surgery often still involves anti-rejection drugs. These medications protect a hard-won organ, but long-term use also brings risks of infection and other health problems. The University of California, Los Angeles (UCLA), in the United States, is exploring another path: helping the immune system gradually accept a transplanted liver, potentially allowing some patients to stop medication.

NBC News reported that physicians are extending a stem cell strategy previously used in kidney transplantation to liver transplantation. UCLA’s trial registry entry further shows that this early study, numbered NCT07269041, plans to enroll 12 people and is led by Jeffrey Veale. The registry lists a start date of February 2026 and an estimated completion date of January 2033. The information currently available for verification describes the research plan; it does not yet provide results showing successful medication withdrawal in liver transplant participants.

The approach, called “delayed immune tolerance,” centers on infusing blood-forming stem and progenitor cells from the original donor after the organ transplant has been completed and the patient’s recovery has stabilized. Researchers hope donor-derived blood-forming cells will coexist with the recipient’s cells, creating a state of “mixed chimerism” that enables the immune system to accept a liver from the same donor. UCLA has previously gained experience withdrawing medication in some kidney transplant patients, but whether this can be replicated in liver transplantation remains a question for this trial to test.

Before the cell infusion, participants must undergo two weeks of total lymphoid irradiation and treatment with rabbit antithymocyte globulin to create conditions that allow donor cells to persist, with the cells infused on the final day. Under the registered study design, treatment can take place on an outpatient basis. Participants must subsequently undergo regular blood tests, assessments of transplanted liver function, and liver biopsies to monitor for rejection.

Medication withdrawal has clear thresholds. The study plans to begin gradually reducing tacrolimus in the sixth month after infusion, with the goal of discontinuing it between months 10 and 12. Prerequisites include donor cell chimerism remaining detectable for at least 180 days, liver function meeting stability criteria, and no rejection confirmed clinically or by biopsy, as well as no graft-versus-host disease. The latter is a complication in which donor immune cells attack the recipient’s tissues, and it is a risk the study must guard against.

The trial’s eligible patient population is quite limited: participants must be adults who received a living-donor liver transplant at least one year and no more than 20 years earlier, and they must meet specified human leukocyte antigen (HLA) matching criteria with their original donor. The original donor must also be able to provide blood-forming cells again. As a result, this design cannot currently include all liver transplant patients, and it cannot be directly extended to people who received organs from deceased donors.

For the 12 planned participants, the study will assess more than whether they can take less medication. It will examine whether the risks of the conditioning treatment and cell infusion can yield durable, safe immune tolerance. Even if medication withdrawal succeeds in the short term, whether the transplanted liver can maintain its function over the long term will require further follow-up. This trial brings experience accumulated in kidney transplantation to another organ and will test how far this approach can go.

References

  1. NBC News
  2. UCLA Clinical Trials